An update on tolvaptan for autosomal dominant polycystic kidney disease.

Poch, E; Rodas, L; Blasco, M; Molina, A; Quintana, L

Poch, E; Rodas, L; Blasco, M; Molina, A; Quintana, L.

Affiliation

Poch E; Department of Nephrology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain. EPOCH@clinic.cat.
Rodas L; Department of Nephrology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Blasco M; Department of Nephrology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Molina A; Department of Nephrology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Quintana L; Department of Nephrology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.

Drugs Today (Barc) ; 54(9): 519-533, 2018 Sep.

Article in En | MEDLINE | ID: mdl-30303493

Subject(s)

Antidiuretic Hormone Receptor Antagonists/therapeutic use; Polycystic Kidney, Autosomal Dominant/drug therapy; Tolvaptan/therapeutic use; Clinical Trials as Topic; Drug Interactions; Humans; Tolvaptan/adverse effects; Tolvaptan/pharmacokinetics; Tolvaptan/pharmacology

Key words

Aquaretic agents; Autosomal dominant poly-cystic kidney disease; Renal disorders; Tolvaptan; Vasopressin antagonists

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polycystic Kidney, Autosomal Dominant / Antidiuretic Hormone Receptor Antagonists / Tolvaptan Type of study: Clinical_trials Limits: Humans Language: En Journal: Drugs Today (Barc) Year: 2018 Document type: Article

Fulltext

XML

PubMed Links

Search on Google